• Completed

GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex

Time Frame: 2010 and 2016


Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

gmmg relapse

Eudra CT-No: 2009-013856-61.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE



German-speaking myeloma multicenter group (GMMG)



Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Leukemia; 2021

Click here for details


GMMG - The German Speaking Myeloma Multicenter Group

 

731. CLINICAL AUTOLOGOUS TRANSPLANTATION: RESULTS: MULTIPLE MYELOMA: SALVAGE AUTOLOGOUS TRANSPLANTS, MINIMAL RESIDUAL DISEASE, AND CHECKPOINT INHIBITORS| NOVEMBER 29, 2018


Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse


Click here for details







Posts Archive